Compound ID | 626
Class: Beta-lactam (monobactam)
Spectrum of activity: | Gram-positive |
Details of activity: | Potent against Gram negatives, was intended to go into clinical trials for Pseudomonas infections. |
Institute where first reported: | PanTherix Ltd, UK (Licensed); Naeja Pharmaceutical Inc, Canada (Ceased R&D) |
Year first mentioned: | 2003 |
Highest developmental phase: | Preclinical |
Development status: | Inactive |
Reason Dropped: | PanTherix couldn't raise $15 million to take this further (1) |
Chemical structure(s): | |||||||||||
|
|
External links: | |
PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/129846797 |
Citations: |
|